GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » PE Ratio

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) PE Ratio : At Loss (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-16), Panacea Life Sciences Holdings's share price is $0.1384. Panacea Life Sciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.46. Therefore, Panacea Life Sciences Holdings's PE Ratio for today is At Loss.

Panacea Life Sciences Holdings's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.46.

As of today (2024-05-16), Panacea Life Sciences Holdings's share price is $0.1384. Panacea Life Sciences Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.41. Therefore, Panacea Life Sciences Holdings's PE Ratio without NRI ratio for today is At Loss.

Panacea Life Sciences Holdings's EPS without NRI for the three months ended in Mar. 2024 was $-0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.41.

During the past 3 years, the average EPS without NRI Growth Rate was -11.60% per year.

During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average EPS without NRI Growth Rate was -11.60% per year. The lowest was -11.60% per year. And the median was -11.60% per year.

Panacea Life Sciences Holdings's EPS (Basic) for the three months ended in Mar. 2024 was $-0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.46.

Back to Basics: PE Ratio


Panacea Life Sciences Holdings PE Ratio Historical Data

The historical data trend for Panacea Life Sciences Holdings's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings PE Ratio Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PE Ratio
N/A N/A At Loss At Loss

Panacea Life Sciences Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Panacea Life Sciences Holdings's PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Life Sciences Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's PE Ratio falls into.



Panacea Life Sciences Holdings PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Panacea Life Sciences Holdings's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.1384/-0.460
=-0.3(At Loss)

Panacea Life Sciences Holdings's Share Price of today is $0.1384.
Panacea Life Sciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Panacea Life Sciences Holdings  (OTCPK:PLSH) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Panacea Life Sciences Holdings PE Ratio Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
Executives
Leslie Buttorff director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER 16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger director 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman officer: CONTROLLER & PRIN ACTNG OFCR 16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc. 10 percent owner 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner 10 percent owner 65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert director 170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du officer: Chief Growth Officer 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis director 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky director, 10 percent owner 332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz director 332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson officer: Chief Strategy Officer 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi officer: President 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert director, officer: Executive Chairman 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price director 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval director NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Headlines

From GuruFocus

Panacea Announces Letter of Intent to Acquire N7 Enterprises, Inc.

By Stock market mentor Stock market mentor 01-23-2023